Expert cardiologists discuss the progressive nature of heart failure and the associated risk factors of diabetes on HF.
March 10th 2021, 10:00pm
When comparing 1-step and 2-step approaches for diagnosing gestational diabetes among pregnant women, researchers found no significant between-group differences in the risks of primary outcomes relating to perinatal and maternal complications.
March 9th 2021, 2:00pm
Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.
March 2nd 2021, 5:05pm
Timing of bout-related moderate-to-vigorous physical activity (MVPA) is associated with cardiorespiratory fitness and cardiovascular risk among men with type 2 diabetes (T2D), independent of bout-related MVPA volume and intensity, according to research published in Diabetes Care.
March 2nd 2021, 2:00pm
Medicare Advantage enrollees are more likely to be treated with metformin and sulfonylureas and less likely to receive costly newer medications than those in traditional Medicare.
March 1st 2021, 4:39pm
Collaboration enabled ChristianaCare to significantly grow its population of patients with well-controlled disease, thanks to a diabetes control roadmap that ensured both physical and emotional health needs were met through interprofessional partnerships.
February 25th 2021, 7:00pm
Genetically decreased vitamin D levels are unlikely to have a large effect on risk of type 1 diabetes, according to results of a Mendelian randomization study published in PLOS Medicine.
February 22nd 2021, 7:15pm
Low-quality maternal diets may increase the odds of offspring being considered overweight or obese, according to study results published in BMC Medicine.
February 18th 2021, 5:25pm
The SURPASS program, which consists in part of SURPASS-3 and SURPASS-5, is testing the efficacy and safety of tirzepatide, a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
February 10th 2021, 10:00pm
In the placebo-controlled trial, 86% of participants who received semaglutide attained at least a 5% reduction in total body weight.
February 9th 2021, 1:44pm
On this episode of Managed Care Cast, we speak with experts from ChristianaCare, which implemented a diabetes pilot program at 4 of its primary care sites in 2019 and saw its population of patients with well-controlled disease grow by 16%.
